五价人牛重配轮状病毒活疫苗(RV5)在中国健康婴儿中的效力和安全性:一项随机双盲安慰剂对照试验
这项在中国健康婴儿中开展的多中心随机双盲安慰剂对照试验共纳入4040名6-12周龄婴儿,按1:1随机接受3剂口服RV5疫苗或安慰剂。结果显示RV5对任何血清型所致任何严重程度轮状病毒胃肠炎的效力为69.3%(95%CI:54.5,79.7),对严重轮状病毒胃肠炎的效力为78.9%(95%CI:59.1,90.1);疫苗组与安慰剂组不良事件发生率相近,未发现与疫苗相关的严重不良事件。
要点
- RV5对任何血清型所致任何严重程度RVGE的效力为69.3%(95%CI:54.5,79.7)。
- RV5对任何血清型所致严重RVGE的效力为78.9%(95%CI:59.1,90.1)。
- 疫苗组与安慰剂组不良事件和严重不良事件发生率相近,未发现疫苗相关严重不良事件。
核心结论
- 在中国婴儿中,RV5对任何血清型所致任何严重程度和严重轮状病毒胃肠炎均有效力,且就不良事件而言总体耐受性良好。
研究设计与样本
- 在中国健康婴儿中开展的多中心随机双盲安慰剂对照试验,共纳入4040名6-12周龄参与者,随机分配至3剂口服RV5组(n=2020)或安慰剂组(n=2020),间隔约4周给药。
- 参与者以同时或错开方式接种OPV和DTaP。
- 主要目标为评估第三剂后至少14天针对自然发生RVGE的疫苗效力,关键次要目标包括针对自然发生的严重RVGE以及针对疫苗所含轮状病毒血清型所致任何严重程度和严重RVGE的效力。
- 每剂后30天内收集所有不良事件,整个研究期间收集严重不良事件和肠套叠病例。
- 临床试验注册号:NCT02062385。
主要发现
- 针对任何血清型所致任何严重程度RVGE的疫苗效力为69.3%(95%CI:54.5,79.7)。
- 针对任何血清型所致严重RVGE的效力为78.9%(95%CI:59.1,90.1)。
- 针对疫苗所含血清型所致任何严重程度RVGE的效力为69.9%(95%CI:55.2,80.3),针对疫苗所含血清型所致严重RVGE的效力为78.9%(95%CI:59.1,90.1)。
- 任何剂次接种后30天内,疫苗组53.5%(1079/2015)和安慰剂组53.3%(1077/2019)的参与者报告至少1起不良事件;疫苗组5.8%(116/2015)和安慰剂组5.7%(116/2019)报告严重不良事件。
- 未发现RV5接种者中的严重不良事件与疫苗相关;RV5接种者中报告2例肠套叠病例,经治疗后恢复,均被认为与疫苗无关。
关键数值与推荐
- 主要目标:第三剂后至少14天针对自然发生RVGE的疫苗效力。
- 关键次要目标:针对自然发生严重RVGE的效力,以及针对疫苗所含轮状病毒血清型所致任何严重程度和严重RVGE的效力。
- 任何血清型所致任何严重程度RVGE的效力为69.3%(95%CI:54.5,79.7)。
- 任何血清型所致严重RVGE的效力为78.9%(95%CI:59.1,90.1)。
- 疫苗所含血清型所致任何严重程度RVGE的效力为69.9%(95%CI:55.2,80.3),所致严重RVGE的效力为78.9%(95%CI:59.1,90.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE). METHODS: 4040 participants aged 6-12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385). RESULTS: VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related. CONCLUSIONS: In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.
引用
- Mo Z, Mo Y, Li M, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. Vaccine. 2017. PMID: 28935470. doi:10.1016/j.vaccine.2017.08.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。